Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast

被引：0

作者：

Takano, Yuko ^{[1
,2
]}

Mizuno, Kazuyuki ^{[1
]}

Iwase, Madoka ^{[2
]}

Morita, Sachi ^{[1
]}

Torii, Nao ^{[1
,2
]}

Kikumori, Toyone ^{[2
]}

Ando, Yuichi ^{[1
]}

机构：

[1] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

[2] Nagoya Univ Hosp, Dept Breast & Endocrine Surg, Showa Ku, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

来源：

BREAST CANCER | 2025年 / 32卷 / 04期

关键词：

High tumor mutational burden; Invasive lobular carcinoma; Invasive ductal carcinoma; CANCER;

D O I：

10.1007/s12282-025-01706-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00-7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00-6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2- subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.

引用

页码：816 / 825

页数：10

共 19 条

[1] Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry [J].

Adachi, Yayoi ;

Asaga, Sota ;

Kumamaru, Hiraku ;

Kinugawa, Naoko ;

Sagara, Yasuaki ;

Niikura, Naoki ;

Jinno, Hiromitsu ;

Saji, Shigehira ;

Toi, Masakazu .

BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (03) :397-408

[2] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study [J].

Alva, Ajjai S. ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Hansra, Damien ;

Calfa, Carmen J. ;

Khalil, Maged F. ;

Ahn, Eugene R. ;

Cannon, Timothy L. ;

Crilley, Pamela ;

Fisher, Julie G. ;

Haslem, Derrick S. ;

Shrestha, Sagun ;

Antonelli, Kaitlyn R. ;

Butler, Nicole L. ;

Warren, Sasha L. ;

Rygiel, Andrew L. ;

Ranasinghe, Shamika ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) :2443-+

[3] The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies [J].

Angus, Lindsay ;

Smid, Marcel ;

Wilting, Saskia M. ;

van Riet, Job ;

Van Hoeck, Arne ;

Luan Nguyen ;

Nik-Zainal, Serena ;

Steenbruggen, Tessa G. ;

Tjan-Heijnen, Vivianne C. G. ;

Labots, Mariette ;

van Riel, Johanna M. G. H. ;

Bloemendal, Haiko J. ;

Steeghs, Neeltje ;

Lolkema, Martijn P. ;

Voest, Emile E. ;

van de Werken, Harmen J. G. ;

Jager, Agnes ;

Cuppen, Edwin ;

Sleijfer, Stefan ;

Martens, John W. M. .

NATURE GENETICS, 2019, 51 (10) :1450-+

[4] Prevalence and mutational determinants of high tumor mutation burden in breast cancer [J].

Barroso-Sousa, R. ;

Jain, E. ;

Cohen, O. ;

Kim, D. ;

Buendia-Buendia, J. ;

Winer, E. ;

Lin, N. ;

Tolaney, S. M. ;

Wagle, N. .

ANNALS OF ONCOLOGY, 2020, 31 (03) :387-394

[5] Genomic characterization of metastatic breast cancers [J].

Bertucci, Francois ;

Ng, Charlotte K. Y. ;

Patsouris, Anne ;

Droin, Nathalie ;

Piscuoglio, Salvatore ;

Carbuccia, Nadine ;

Soria, Jean Charles ;

Dien, Alicia Tran ;

Adnani, Yahia ;

Kamal, Maud ;

Garnier, Severine ;

Meurice, Guillaume ;

Jimenez, Marta ;

Dogan, Semih ;

Verret, Benjamin ;

Chaffanet, Max ;

Bachelot, Thomas ;

Campone, Mario ;

Lefeuvre, Claudia ;

Bonnefoi, Herve ;

Dalenc, Florence ;

Jacquet, Alexandra ;

De Filippo, Maria R. ;

Babbar, Naveen ;

Birnbaum, Daniel ;

Filleron, Thomas ;

Le Tourneau, Christophe ;

Andre, Fabrice .

NATURE, 2019, 569 (7757) :560-+

[6] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[7] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis [J].

Emens, L. A. ;

Adams, S. ;

Barrios, C. H. ;

Dieras, V ;

Iwata, H. ;

Loi, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Winer, E. P. ;

Patel, S. ;

Henschel, V ;

Swat, A. ;

Kaul, M. ;

Molinero, L. ;

Patel, S. ;

Chui, S. Y. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2021, 32 (08) :983-993

[8] Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB [J].

He, Jie ;

Kalinava, Natallia ;

Doshi, Parul ;

Pavlick, Dean C. ;

Albacker, Lee A. ;

Ebot, Ericka M. ;

Tukachinsky, Hanna ;

Pratt, James ;

Fusaro, Gina ;

Oxnard, Geoffrey R. ;

Green, George ;

Fabrizio, David ;

Baden, Jonathan .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)

[9] Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer [J].

Kraya, Adam A. ;

Maxwell, Kara N. ;

Wubbenhorst, Bradley ;

Wenz, Brandon M. ;

Pluta, John ;

Rech, Andrew J. ;

Dorfman, Liza M. ;

Lunceford, Nicole ;

Barrett, Amanda ;

Mitra, Nandita ;

Morrissette, Jennifer J. D. ;

Feldman, Michael ;

Nayak, Anupma ;

Domchek, Susan M. ;

Vonderheide, Robert H. ;

Nathanson, Katherine L. .

CLINICAL CANCER RESEARCH, 2019, 25 (14) :4363-4374

[10] Mutational heterogeneity in cancer and the search for new cancer-associated genes [J].

Lawrence, Michael S. ;

Stojanov, Petar ;

Polak, Paz ;

Kryukov, Gregory V. ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Carter, Scott L. ;

Stewart, Chip ;

Mermel, Craig H. ;

Roberts, Steven A. ;

Kiezun, Adam ;

Hammerman, Peter S. ;

McKenna, Aaron ;

Drier, Yotam ;

Zou, Lihua ;

Ramos, Alex H. ;

Pugh, Trevor J. ;

Stransky, Nicolas ;

Helman, Elena ;

Kim, Jaegil ;

Sougnez, Carrie ;

Ambrogio, Lauren ;

Nickerson, Elizabeth ;

Shefler, Erica ;

Cortes, Maria L. ;

Auclair, Daniel ;

Saksena, Gordon ;

Voet, Douglas ;

Noble, Michael ;

DiCara, Daniel ;

Lin, Pei ;

Lichtenstein, Lee ;

Heiman, David I. ;

Fennell, Timothy ;

Imielinski, Marcin ;

Hernandez, Bryan ;

Hodis, Eran ;

Baca, Sylvan ;

Dulak, Austin M. ;

Lohr, Jens ;

Landau, Dan-Avi ;

Wu, Catherine J. ;

Melendez-Zajgla, Jorge ;

Hidalgo-Miranda, Alfredo ;

Koren, Amnon ;

McCarroll, Steven A. ;

Mora, Jaume ;

Lee, Ryan S. ;

Crompton, Brian ;

Onofrio, Robert .

NATURE, 2013, 499 (7457) :214-218

← 1 2 →